Cybin Inc. - CYBN STOCK NEWS

Cybin Inc. (AMEX:CYBN) has identified Generalized Anxiety Disorder (GAD) as a target indication for its proprietary DMT molecule, CYB004. Preclinical data suggests that CYB004 could effectively treat anxiety disorders, addressing a pressing need given the rising incidence of depression and anxiety, particularly following the pandemic. GAD affects over 40 million adults in the U.S., highlighting the urgency for innovative therapies. Cybin is currently conducting a Phase 1 exploratory trial to assess the safety and dosing of CYB004, with updates expected by the end of February 2023.

Cybin Inc. has outlined its key priorities for 2023, focusing on advancing its CYB003 and CYB004 clinical programs targeting major depressive disorder and anxiety disorders. The Company plans to provide an interim readout of CYB003's Phase 1/2a trial by February 2023, assessing safety and pharmacokinetics. CYB003 aims to improve on oral psilocybin with a more predictable dosing profile. Additionally, the CYB004 program, evaluating intravenous DMT, has shown no significant safety issues and is set to provide updates by February 2023.

Cybin Inc., a biopharmaceutical company, shared a year-end report highlighting key achievements in 2022. The company advanced its leading programs, CYB003 and CYB004, into clinical stages within 18 months of discovery. CYB003, a deuterated psilocybin analog, is set to provide initial safety data in early 2023, while CYB004's Phase I DMT study shows no significant safety issues. Cybin also expanded its intellectual property portfolio and launched a $35 million equity program to support operations and growth.

Cybin Inc. presented new findings on CYB003, a deuterated psilocybin analog, at the ACNP annual meeting in Phoenix, Arizona, from December 4-7, 2022. The data highlights CYB003's pharmacokinetic advantages over classical psilocybin, indicating less variability in plasma levels, faster onset of action, and potentially better tolerability. Currently in a Phase 1/2a clinical trial for major depressive disorder (MDD), these findings strengthen CYB003's therapeutic profile as a promising treatment option for MDD, aiming for shorter treatment times and reduced healthcare burdens.

Cybin Inc. presented significant preclinical data on its deuterated psilocybin analog, CYB003, at Neuroscience 2022 in San Diego, CA. The findings indicate CYB003 exhibits less variability in plasma levels, quicker onset, and shorter duration compared to classical psilocybin. These characteristics may enhance treatment accessibility for major depressive disorder. CYB003 is currently undergoing Phase 1/2a clinical trials, representing a critical step in Cybin's mission to develop effective psychedelic-based therapeutics. This research highlights Cybin's commitment to addressing mental health challenges.

Cybin reported its second-quarter financial results for the period ending September 30, 2022, revealing a net loss of C$10.0 million and cash of C$29.9 million. The company is progressing its clinical pipeline, focusing on modified psychedelic molecules, and enhancing its intellectual property through strategic licensing agreements. Key developments include progress in the CYB004-E Phase 1 trial and the initiation of the CYB003 Phase 1/2a trial for treating major depressive disorder. Cybin also established a US$35 million equity program to support its growth initiatives.

Cybin, a biopharmaceutical company focusing on psychedelics, announced the completion of dosing for four out of five participant cohorts in its CYB004-E Phase 1 trial evaluating DMT. No significant safety issues were reported by the Safety Review Committee. This trial, acquired from Entheon Biomedical in July 2022, is key for the development of CYB004, a DMT molecule aimed at treating anxiety disorders. The study is ongoing in the Netherlands and is expected to finish in the first half of 2023, providing vital safety and dosing data for further development.

Cybin, a biopharmaceutical company advancing psychedelics for therapeutic use, announces participation in key investor events in November 2022. CEO Doug Drysdale will present at the Jefferies London Healthcare Conference on November 15 at 8:00 a.m. GMT and engage in investor meetings. He will also join the Pinsent Masons Psychedelics Panel on November 16 at 5:00 p.m. GMT. Additionally, Drysdale will take part in the PSYCH Investor Event on November 17 for a fireside chat at 5:00 p.m. GMT. Archived webcasts will be available on Cybin’s investor website.

Cybin announced its participation in the Neuropsychiatric & Psychedelics Drug Development Summit from October 31 to November 2, 2022, in Boston, MA. Amy Reichelt, Ph.D., Director of Neuropharmacology, will present findings on CYB004, a deuterated form of DMT aimed at enhancing therapeutic potential. Preclinical data suggests CYB004 has improved bioavailability and a longer duration of action compared to traditional DMT, potentially benefiting patients with mental health conditions.